Gland Pharma Q2 FY27 Profit Jumps 58% as CDMO Grows 31%
Gland Pharma Q2 FY27 net profit rises 58% to ₹291 crore as revenue grows 23% to ₹1,834 crore, led by 31% CDMO growth and a 42% jump in US sales.
Gland Pharma Q2 FY27 net profit rises 58% to ₹291 crore as revenue grows 23% to ₹1,834 crore, led by 31% CDMO growth and a 42% jump in US sales.
Emcure Pharmaceuticals Q2 FY27 profit rose 29.3% to ₹325.1 crore as revenue grew 24.3% to ₹2,820.5 crore, led by 34.5% growth in international sales.
Laurus Labs reported Q2 FY27 net profit of ₹441 crore, up 126%, on revenue of ₹2,206 crore, as CDMO revenue rose 75% to ₹904 crore and EBITDA margin widened to 34.5%. The Hyderabad drugmaker also agreed to take a 60% stake in Montreal-based Galenvs Sciences to deepen its oligonucleotide capabilities.
Ahmedabad-based fermentation API maker Concord Biotech grew Q2 FY27 revenue 25% to ₹309.1 crore as API sales rose 30%, while solvent and power costs trimmed gross margin; the company added two US ANDA approvals, launched its Inspira dermatology division and is chasing injectables contracts.
Jagsonpal Pharmaceuticals’ consolidated Q2 FY27 revenue rose 29% to ₹96.4 crore as Aequitas Healthcare was consolidated for the first time, while the company said it expects quarterly revenue to cross ₹100 crore in Q3 after adding Group Pharma’s wellness portfolio.
Syngene International’s Q2 FY27 revenue rose 13% quarter-on-quarter to ₹833 crore and operating EBITDA margin improved six points to 18%, helped by CDMO traction, while the company signed its first manufacturing agreement for its Bayview biologics facility in the US.
Morepen Laboratories reported Q2 FY27 revenue of ₹755 crore, up 81%, and EBITDA of ₹132 crore, up 273%, as its CDMO business hit commercial scale, exports more than doubled and it filed its first US ANDA.
Mankind Pharma’s Q2 FY27 net profit rose 37.7% to ₹716 crore on 17.3% revenue growth to ₹4,338 crore, led by cardiac and anti-diabetes demand in India, 33% export growth and a 210 bps EBITDA margin expansion to 27.1%.
Cipla’s consolidated net profit fell about 35% year-on-year to ₹878 crore in Q2 FY27 on revenue of ₹7,404 crore, but its One India business logged its highest-ever quarterly sales, margins improved sequentially, and the company is leaning on its US inhalation pipeline and a Keytruda biosimilar partnership for growth.